Grants for Pediatric Pneumococcal Surveillance Studies (Saudi Arabia) support research aimed at addressing critical gaps in understanding pneumococcal disease burden and serotype epidemiology in children in Saudi Arabia.

Overview

This research grant opportunity focuses on surveillance studies concerning invasive and non-invasive pneumococcal disease serotype distribution in children under five years of age, utilizing samples collected between 2023 and 2029. The scope of work includes investigating the genetic evolution of pneumococci following immunization programs with pneumococcal conjugate vaccines and analyzing antibiotic sensitivity patterns of Streptococcus pneumoniae in young children. The initiative underscores the ongoing need for comprehensive data to support informed public health decisions in Saudi Arabia.

Applicants are encouraged to design studies employing prospective or bidirectional cohort surveillance methods to generate robust and actionable data. Collaborative, multicenter studies are encouraged, provided all participating entities have clearly defined roles and the primary applicant maintains a central role in the project.

Funding and Benefits

• Grant Size: $100,000 to $500,000
• Maximum Funding Available: Up to 400,000 USD per project, with the possibility of higher funding considered on a case-by-case basis.
• Maximum Duration: Three years.

Eligibility

Eligible applicants must be organizations based in Saudi Arabia. The Principal Investigator must hold appropriate medical, scientific, nursing, or pharmacy qualifications and be affiliated with the applying institution.

Application Process

The application process requires the submission of a proposal detailing the proposed surveillance methods and research scope. Interested parties may apply via the designated link.

Apply Here

Deadline and Timeline

• Closing Date: 31 May 2026
• Post Date: April 07, 2026

About the Funder

The Pfizer Foundation, Inc. is a charitable organization founded by Pfizer Inc. The Foundation works to address the challenges of a complex and evolving global health landscape. It provides funding and resources to support programs that nurture science and innovation, reduce the threat of disease, strengthen healthcare capacity, ensure access to quality care, address immediate disaster and humanitarian health needs, and enhance the community involvement of Pfizer colleagues.